Patents by Inventor Altaf A. Dar

Altaf A. Dar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MIR-18B for use as a marker of cancer progression and target for therapies to treat cancer
    Patent number: 11142796
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of miR-18b. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of miR-18b between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising miR-18b and/or an agent that enhances the expression of miR-18b.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: October 12, 2021
    Assignee: Sutter Bay Hospitals
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • FALZ for use as a target for therapies to treat cancer
    Patent number: 10526662
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: January 7, 2020
    Assignee: Sutter Bay Hospitals
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • FALZ FOR USE AS A TARGET FOR THERAPIES TO TREAT CANCER
    Publication number: 20180274041
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.
    Type: Application
    Filed: March 19, 2018
    Publication date: September 27, 2018
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • FALZ for use as a target for therapies to treat cancer
    Patent number: 9920377
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: March 20, 2018
    Assignee: SUTTER WEST BAY HOSPITALS
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • FALZ FOR USE AS A TARGET FOR THERAPIES TO TREAT CANCER
    Publication number: 20160024590
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.
    Type: Application
    Filed: March 15, 2014
    Publication date: January 28, 2016
    Applicant: Sutter West Bay Hospitals
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar
  • MIR-18B FOR USE AS A MARKER OF CANCER PROGRESSION AND TARGET FOR THERAPIES TO TREAT CANCER
    Publication number: 20150211071
    Abstract: The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of miR-18b. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of miR-18b between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising miR-18b and/or an agent that enhances the expression of miR-18b.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 30, 2015
    Inventors: Mohammed Kashani-Sabet, Altaf A. Dar